{
  "variant_id": {
    "Gene": "PARK2",
    "Protein_Change": {
      "ref": "L",
      "alt": "R",
      "position": "66"
    },
    "variant_string_id": "PARK2 L66R"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The study shows that the Lys66Arg variant in PARK2 impairs ubiquitination and proteasome activity, key mechanisms in Parkinson's disease (PARK2) pathogenesis.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links the variant to a well-characterized disease mechanism (ubiquitination dysfunction) relevant to PARK2."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study uses ubiquitination assays and proteasome activity assays, which are standard functional assays for evaluating PARK2-related pathogenicity.",
      "judgment": "Yes",
      "reasoning": "These assays directly model the molecular defect (ubiquitination dysfunction) central to PARK2 pathogenesis.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "sub_steps": [
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes wild-type and mutant controls, and experiments were performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both controls and replicates are explicitly mentioned, satisfying the criteria for Sub-step 3a.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the Lys66Arg variant to known pathogenic variants in PARK2, validating its functional impact.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are used as controls, strengthening the assay's validity.",
          "next_step_or_outcome": "Proceed to Step 4"
        }
      ]
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "sub_steps": [
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reports statistically significant differences in ubiquitination and proteasome activity (p < 0.001).",
          "judgment": "Yes",
          "reasoning": "Robust statistical analysis with p-values supports OddsPath calculation.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The Lys66Arg variant shows a >10-fold reduction in proteasome activity compared to wild-type, aligning with OddsPath > 18.7 thresholds.",
          "judgment": "Yes",
          "reasoning": "The functional defect is quantitatively severe, exceeding OddsPath thresholds for PS3_very_strong.",
          "next_step_or_outcome": "Finalize evidence strength"
        }
      ]
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The Lys66Arg variant in PARK2 shows a >10-fold reduction in proteasome activity and impaired ubiquitination, consistent with OddsPath > 18.7 thresholds, providing very strong pathogenic evidence (PS3_very_strong)."
}